David Nierengarten

Stock Analyst at Wedbush

(4.51)
# 322
Out of 5,182 analysts
233
Total ratings
57.21%
Success rate
19.2%
Average return

Stocks Rated by David Nierengarten

Perspective Therapeutics
Apr 20, 2026
Reiterates: Outperform
Price Target: $11
Current: $3.95
Upside: +178.48%
Kiniksa Pharmaceuticals International,
Apr 16, 2026
Maintains: Outperform
Price Target: $53$58
Current: $53.85
Upside: +7.71%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $12.12
Upside: +48.51%
Nuvation Bio
Apr 16, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.56
Upside: +141.23%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.71
Upside: +93.74%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65$80
Current: $68.63
Upside: +16.57%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.44
Upside: +110.73%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $101.94
Upside: +22.62%
ORIC Pharmaceuticals
Apr 1, 2026
Maintains: Outperform
Price Target: $20$17
Current: $9.65
Upside: +76.17%
Scholar Rock Holding
Apr 1, 2026
Maintains: Outperform
Price Target: $56$58
Current: $46.73
Upside: +24.12%
Reiterates: Outperform
Price Target: $30
Current: $21.92
Upside: +36.86%
Reiterates: Outperform
Price Target: $55
Current: $36.34
Upside: +51.35%
Reiterates: Outperform
Price Target: $1,000
Current: $775.03
Upside: +29.03%
Maintains: Outperform
Price Target: $4$8
Current: $7.53
Upside: +6.24%
Maintains: Outperform
Price Target: $4$5
Current: $1.26
Upside: +296.83%
Maintains: Outperform
Price Target: $90$95
Current: $85.37
Upside: +11.28%
Maintains: Outperform
Price Target: $57$65
Current: $30.56
Upside: +112.70%
Initiates: Underperform
Price Target: $110
Current: $109.87
Upside: +0.12%
Maintains: Outperform
Price Target: $110$88
Current: $67.26
Upside: +30.84%
Reiterates: Outperform
Price Target: $31
Current: $23.71
Upside: +30.75%
Reiterates: Outperform
Price Target: $25
Current: $8.80
Upside: +184.09%
Maintains: Neutral
Price Target: $9$7
Current: $13.20
Upside: -46.97%
Upgrades: Outperform
Price Target: $5$7
Current: $1.30
Upside: +438.46%
Reiterates: Outperform
Price Target: $26
Current: $12.15
Upside: +113.99%
Reiterates: Neutral
Price Target: $8
Current: $14.38
Upside: -44.37%
Downgrades: Neutral
Price Target: $80$20
Current: $34.87
Upside: -42.64%
Maintains: Outperform
Price Target: $40
Current: $66.11
Upside: -39.49%
Initiates: Outperform
Price Target: $40
Current: $73.99
Upside: -45.94%
Initiates: Outperform
Price Target: $18
Current: $9.07
Upside: +98.46%
Reiterates: Outperform
Price Target: $12
Current: $3.69
Upside: +225.20%
Maintains: Equal-Weight
Price Target: $1,400$500
Current: $1.13
Upside: +44,147.79%
Maintains: Neutral
Price Target: $105$60
Current: $8.60
Upside: +597.67%
Maintains: Outperform
Price Target: $71$75
Current: $24.53
Upside: +205.75%
Downgrades: Neutral
Price Target: n/a
Current: $1.44
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $3.77
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $11.51
Upside: -